36 min listen
Expert Insights Into the Biosafety of Oncolytic Immunotherapies and Their Combination With Immune Checkpoint Inhibitors
Expert Insights Into the Biosafety of Oncolytic Immunotherapies and Their Combination With Immune Checkpoint Inhibitors
ratings:
Length:
30 minutes
Released:
Jun 23, 2023
Format:
Podcast episode
Description
Do you know how the biosafety risks of oncolytic immunotherapies and their combination with immune checkpoint inhibitors can be mitigated? Credit available for this activity expires: 6/22/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/993479?ecd=bdc_podcast_libsyn_mscpedu
Released:
Jun 23, 2023
Format:
Podcast episode
Titles in the series (100)
Acute Myeloid Leukemia Beyond FLT3 and IDH: The Role of Non-Targetable Driver Mutations: Do you understand the role of non-targetable driver mutations in the management of acute myeloid leukemia (AML)? Credit available for this activity expires: 5/1/2024 Earn Credit / Learning Objectives & Disclosures: by Keeping Current CME